Suven Life Sciences Ltd (Suven) announced that the European Patent Office (EPO) has issued a product Patent:, EP1919896 to one of their New Chemical Entity (NCE) which is for the treatment of disorders associated with neurodegenerative diseases and this patent is valid until 2025.
The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.
With this new patent, Suven has a total of eight granted European product patents for their NCEs in CNS therapy. All the eight EPO patents have been validated in the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland etc.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal drug discovery research efforts. Products out of these inventions may be out-licensed at various phases of pre-clinical and clinical development.
"We are very pleased by the grant of this patent to Suven by European Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated US$ 20 billion market potential globally," said Venkat Jasti, CEO of Suven.